Rituximab biosimilar - Boehringer Ingelheim

Drug Profile

Rituximab biosimilar - Boehringer Ingelheim

Alternative Names: BI-695500

Latest Information Update: 17 Aug 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Follicular lymphoma; Rheumatoid arthritis

Most Recent Events

  • 01 Aug 2016 Boehringer Ingelheim terminates a phase III trial for Follicular lymphoma (First-line therapy) in USA (NCT02417129)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Dec 2015 Boehringer completes a phase I trial in Follicular lymphoma (First-line therapy) in Austria, Australia, Belgium, Croatia, Czech Republic, Germany, France, Greece, Hungary, Poland, Russia, Slovakia, Spain and New Zealand (IV) (NCT01950273)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top